RxDoctor Payments Data

William Reid, MD

Pulmonary Disease · Meridian, MSNPI 1760469340

Payments from drug & device makers

$918in general payments, 2019–2025

Across 50 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$305
  • Sanofi$115
  • Boehringer Ingelheim$109
  • Verona Pharma, Inc.$86
  • Viatris Specialty LLC$57
  • GSK$51
  • plus $195 from 7 others

What the payments were for

  • Food & beverage$918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$918 in reported general payments places this provider in the 25th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$161,934
Medicare patients
690
Services billed
2,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate26$268,041
Fasenra PenBenralizumab23$127,198
Dupixent PenDupilumab17$59,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$58,674
EliquisApixaban79$56,975
TrulicityDulaglutide47$52,023
Breo ElliptaFluticasone/Vilanterol78$32,864
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$27,059
JardianceEmpagliflozin34$23,706
JanuviaSitagliptin Phosphate20$18,676
FarxigaDapagliflozin Propanediol32$18,385
Praluent PenAlirocumab29$16,462
OzempicSemaglutide18$15,926
SymbicortBudesonide/Formoterol Fumarate46$15,567
Combivent RespimatIpratropium/Albuterol Sulfate18$14,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Jardiance, Combivent Respimat, Synjardy Xr, Spiriva Respimat$109$321,401103 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$51$93,934150 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$29$61,010112 claims
AbbVieSynthroid$38$2,80942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →